Collegium Pharm Inc patents expiration
1. Nucynta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(1 year, 8 months ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071970 | COLLEGIUM PHARM INC | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 15 October, 2012
Treatment: Relief of moderate to severe acute pain; Management of moderate to severe acute pain
Dosage: SOLUTION;ORAL; TABLET;ORAL
NUCYNTA family patents
2. Nucynta Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(1 year, 8 months ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071970 | COLLEGIUM PHARM INC | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun, 2017
(6 years ago) | |
| US11007156 | COLLEGIUM PHARM INC | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
Oct, 2022
(1 year, 6 months ago) | |
| US8075872 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8420056 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8309060 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8114383 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Oct, 2024
(5 months from now) | |
| US11344512 | COLLEGIUM PHARM INC | Titration of tapentadol |
Apr, 2028
(3 years from now) | |
| US8536130 | COLLEGIUM PHARM INC | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
Sep, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: Relief of moderate to severe chronic pain; A method of titrating an opioid to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatme...
Dosage: TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER family patents
3. Xtampza Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10525053 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
| US9248195 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
| US10525052 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(9 months ago) | |
| US8840928 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
| US9763883 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jul, 2023
(9 months ago) | |
| US9592200 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Jul, 2023
(9 months ago) | |
| US9044398 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Jul, 2023
(9 months ago) | |
| US8557291 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
Mar, 2025
(10 months from now) | |
| US7399488 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar, 2025
(10 months from now) | |
| US7771707 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(10 months from now) | |
| US8449909 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(10 months from now) | |
| US8758813 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Jun, 2025
(1 year, 1 month from now) | |
| US10668060 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
| US9682075 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
| US10004729 | COLLEGIUM PHARM INC | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
Dec, 2030
(6 years from now) | |
| US9737530 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
| US9968598 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
| US10188644 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
| US10646485 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2019 |
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER family patents